CHRS News and Press, Coherus BioSciences Inc. From 04/08/24

– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion – – Mechanism may enhance antitumor responses with immunothera...

2024-04-05 16:42:08 ET Gainers: Applied Optoelectronics ( AAOI ) +4% . Outset Medical ( OM ) +2% . SunPower Corporation ( SPWR ) +2% . Applied Therapeutics ( APLT ) +2% . Enovix Corporation ( ENVX ) +2% . Losers: Palladyn...

2024-03-20 20:14:44 ET Summary CHRS has sold Cimerli, a Lucentis biosimilar, to SDZNY. CHRS anti-IL-27 antibody, casdozokitug, shows promising results as part of a triple therapy in hepatocellular carcinoma, with an overall response rate of 38%. Numbers on market share point t...

2024-03-14 18:28:43 ET The final set of results for Coherus Biosciences ' (NASDAQ: CHRS) 2023 was released after market hours on Wednesday, and investors reacted with displeasure the following day. They traded the stock down by more than 6% Thursday, a much steeper fall than the 0.6...

2024-03-14 11:22:56 ET More on Coherus BioSciences Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript Coherus BioSciences: FDA Approvals Spice Up The Pipeline Coherus BioSciences Q4 2023 Earnings Preview Biggest stock movers today: Boeing, NuSt...

2024-03-14 08:28:15 ET Losers: Spruce Biosciences ( SPRB ) -78% reports FY results Solidion Technology ( STI ) -30% climbs 10% on $3.85M private placement . Hello Group ( MOMO ) -16% after Q4 earnings release . Pagaya Technologies Ltd ( ...

2024-03-13 20:56:10 ET Coherus BioSciences, Inc. (CHRS) Q4 2023 Results Conference Call March 13, 2024 05:00 PM ET Company Participants Jamie Taylor - Head of Investor Relations Dennis Lanfear - Chief Executive Officer Paul Reider - Chief Commercial Officer R...

2024-03-13 16:12:50 ET More on Coherus BioSciences Coherus BioSciences: FDA Approvals Spice Up The Pipeline Coherus BioSciences Q4 2023 Earnings Preview Biggest stock movers today: Boeing, NuStar Energy, Archer-Daniels-Midland, and more Read the full articl...

– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA ® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI ® net sales of $52.4 milli...

SuRo Capital Corp. (SSSS) is expected to report for quarter end 2023-12-31 Enviva Inc. (EVA) is expected to report $-0.76 for Q4 2023 Jushi Holdings Inc. - Class B (Sub Voting) (JUSHF) is expected to report $-0.04 for Q4 2023 U Power Limited (UCAR) is expected to report for quarter en...